Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 2977  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Articlesmenu-bullet Search Instructions Online Submission Subscribe Etcetera Contact
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (215 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  References
 ::  Article Tables

 Article Access Statistics
    PDF Downloaded24    
    Comments [Add]    

Recommend this journal


  Table of Contents     
Year : 2011  |  Volume : 57  |  Issue : 2  |  Page : 178-179

Moderate cytopenias in asymptomatic individuals: Is screening for autoimmune connective tissue diseases warranted?

1 Medical Oncology and Blood Disorders, LLP, Hartford, CT; Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA
2 Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA

Date of Web Publication4-Jun-2011

Correspondence Address:
C A Dasanu
Medical Oncology and Blood Disorders, LLP, Hartford, CT; Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0022-3859.81864

Rights and Permissions

How to cite this article:
Dasanu C A, Do C. Moderate cytopenias in asymptomatic individuals: Is screening for autoimmune connective tissue diseases warranted?. J Postgrad Med 2011;57:178-9

How to cite this URL:
Dasanu C A, Do C. Moderate cytopenias in asymptomatic individuals: Is screening for autoimmune connective tissue diseases warranted?. J Postgrad Med [serial online] 2011 [cited 2023 Jun 1];57:178-9. Available from:


To date no clear-cut guidelines exist for the evaluation of asymptomatic patients presenting with pancytopenia or bicytopenia. Experts suggest evaluation for any evidence of peripheral destruction / consumption (e.g., drug-induced causes, hypersplenism, disseminated intravascular coagulation, etc.), if clinical suspicion exists. Furthermore, evaluation for central causes such as vitamin B12 / folate deficiency, various bone marrow failure syndromes, and lymphoproliferative conditions is also recommended.

We retrospectively analyzed a series of 35 consecutive patients with persistent pancytopenia or bicytopenia, referred in consultation to our tertiary center. All patients consented to the analysis in accordance with the Declaration of Helsinki. They underwent a detailed medical interview and routine physical examination. Further data was obtained from the medical records. A careful medication history was performed in all the patients. Of note, none of the patients had significant musculoarticular or other complaints. Leukopenia was mild-to-moderate (mean absolute neutrophil count, 1.4 ± 0.5 × 10 6 / mm 3 ) and no increased incidence of infections was present in any of our patients. No platelet aggregation / pseudothrombocytopenia or significant mucosal / cutaneous bleeding was documented in our cohort. The platelet counts were consistent with moderate thrombocytopenia (99 ± 21 × 10 6 / mm 3 ). When present, anemia was not severe (hemoglobin > 9.5 g/dl; erythrocyte count > 3 × 10 6 / mm 3 ). To identify the etiology of the cytopenias, the following workup was initially performed: basic chemistry panel, liver function testing, hepatitis C and B serologies, PT / PTT, fibrinogen, liver-spleen ultrasound, serum vitamin B12 / folic acid, and HIV testing. It also included the hemolytic anemia workup: haptoglobin, lactate dehydrogenase, reticulocyte count, and direct Coombs testing. In all patients, we screened for the presence of collagen vascular disorders, with antinuclear antibodies (ANAs), along with C3 and C4 complement testing. The ANA values were estimated via an immunofluorescence based method.

In eight out of 35 patients, we identified significantly elevated ANA titers (in excess of 1 : 80) with or without a decreased C3 complement level [Table 1]. The C4 was within normal range in all patients. None of the patients was taking any medications associated with drug-induced lupus. Subsequently, an autoimmune connective tissue disorder was diagnosed in seven out of eight patients. The diagnoses were confirmed either via specific antibody panels or clinically, as some patients subsequently became symptomatic. Four of them were diagnosed with systemic lupus erythematosus (SLE), two with mixed connective tissue disease (MCTD), and one with rheumatoid arthritis [Table 1]. The chart analysis showed that five of these patients originally presented with pancytopenia and two with bicytopenias (one with leukopenia-thrombocytopenia and another one with leukopenia-anemia). None of the seven patients with autoimmune connective tissue disease had lymphopenia, autoimmune hemolytic anemia (AIHA) or a positive Coombs test.
Table 1: The laboratory findings in eight out of 35 patients in our cohort presenting with cytopenias

Click here to view

Cytopenias affect up to 40 - 50% of SLE and MCTD patients. [1] Hematological manifestations of SLE include leukopenia, lymphopenia, thrombocytopenia, and / or anemia. Cytopenias in SLE may be drug-induced, indicative of other hematological disease (such as myelofibrosis or myelodysplasia), or most commonly, immune-mediated. This is usually due to excessive antibody-mediated peripheral cell destruction, although antibodies against bone marrow precursors may also play a role. Even if the ANA is positive, the possibility of a non-immune cause for the cytopenia must always be considered. Thrombocytopenia is moderate, but can be severe. Thrombocytopenia in SLE is most commonly immune (SLE-ITP), but may also be related to the presence of the antiphospholipid antibody syndrome. Contrary to popular belief, the most common anemia in SLE is the anemia of chronic disease / inflammation, followed by anemia of renal disease. Although specific, AIHA is rare, as is microangiopathic hemolytic anemia. Of note, immune cytopenias may pre-date the diagnosis of SLE by several years. [2]

A positive ANA result alone is not sufficient for the diagnosis of SLE, because up to 20% of healthy young women may test positive. [3] Moreover, positive ANA results are seen in many other conditions, namely infections, drug use, and some malignancies. [4] Thus, confirmatory testing with specific antibodies and / or a referral to a rheumatologist may be necessary. [5] Leukopenia in autoimmune connective tissue disorders is usually mild and does not require treatment. It is thought to occur via an autoantibody mechanism leading to either immune complex formation or antibody/complement-dependent cellular cytotoxicity (ADCC or ACDCC). As a result, the C3 and / or C4 levels may be depressed in patients with active SLE, because of their consumption in immune complex-induced inflammation, clearance in the spleen or use in ACDCC. It should also be borne in mind that C4 tends to be less helpful due to the presence of null alleles, but in practice both C3 and C4 are usually measured together. A specific antibody testing should of course be arranged if the initial ANA is positive and there is sufficient clinical concern about the underlying systemic autoimmunity. The titer, and especially the pattern of the specific antibody testing, strongly enhance the ability to discriminate between ANA-positive healthy individuals and patients with autoimmune connective tissue disease. [6]

Given the findings in our patients, we believe that screening for an autoimmune connective tissue disease with serum ANA and C3 complement levels is warranted in the initial evaluation of patients presenting with asymptomatic pancytopenia or bicytopenia (especially when leukopenia is part of the picture). We believe these simple tests may prevent further, more expensive and / or invasive tests, such as, flow cytometry and / or bone marrow aspiration and biopsy. This testing may lead to an early diagnosis of a systemic inflammatory disorder, which is minimally symptomatic or in a subclinical state. [5],[6] We believe that bone marrow examination is only indicated if there is sufficient concern about an underlying primary hematological disease or in cases of more severe cytopenias. Sensitive yet not very specific, low C3 (and possibly C4) complement levels would point to the disease activity, especially in patients with SLE. [7] Therefore, early diagnosis and treatment of autoimmune connective tissue diseases leading to the resolution of cytopenias appears effective and not cost prohibitive.

 :: References Top

1.Halberg P, Alsbjørn B, Balslev JT, Lorenzen I, Gerstoft J, Ullman S, et al. Systemic lupus erythematosus. Follow-up study of 148 patients. II: Predictive factors of importance for course and outcome. Clin Rheumatolnone 1987;6:22-6.  Back to cited text no. 1
2.Villamin CAnone, Navarra SVnone. Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus. Mod Rheumatolnone 2008;18:161-4.  Back to cited text no. 2
3.Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheumnone 1997;40:1601-11.  Back to cited text no. 3
4.Dasanu CA, Alexandrescu DT. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer. South Med J 2008;101:1161-2.  Back to cited text no. 4
5.Inokuma Snone. How to find a collagen-vascular disease patient in an early stage and when to let her/him visit a rheumatologist. Nippon Rinshonone 2009;67:570-5.  Back to cited text no. 5
6.Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheumnone 2011;63:191-200.  Back to cited text no. 6
7.Fellmann Bnone, Grob PJnone. Systemic lupus erythematosus--clinical aspects and laboratory findings. Schweiz Med Wochenschrnone 1979;109:1237-50.  Back to cited text no. 7


  [Table 1]


Print this article  Email this article
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow